Hodgkin’s and non-Hodgkin’s lymphomas (NHL)

Immunotherapy developments and new agents for locally advanced NSCLC and SCLC

GIST tumours and soft tissue sarcomas

Breast cancer and survivorship

Updates on triple-negative breast cancer and immunotherapy

Gynaecological cancer: New targets and immunotherapy developments

Immunotherapy in NSCLC: Adjuvant and neoadjuvant clinical scenarios

Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC

Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer

Botensilimab plus balstilimab for metastatic heavily pretreated microsatellite stable colorectal cancer

Rationale for routine use of IORT for early breast cancer and data for specific indications

Hormonal Therapy and Complications